Q1 2023 Earnings Forecast for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Issued By SVB Leerink

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, March 1st. SVB Leerink analyst A. Berens expects that the company will post earnings per share of ($0.92) for the quarter. SVB Leerink currently has a “Outperform” rating and a $27.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals’ current full-year earnings is ($4.35) per share. SVB Leerink also issued estimates for Zentalis Pharmaceuticals’ Q2 2023 earnings at ($0.98) EPS, Q3 2023 earnings at ($0.92) EPS, FY2023 earnings at ($4.04) EPS, FY2024 earnings at ($3.89) EPS, FY2025 earnings at ($3.40) EPS and FY2026 earnings at ($2.29) EPS.

ZNTL has been the subject of several other research reports. Guggenheim dropped their price objective on shares of Zentalis Pharmaceuticals from $55.00 to $28.00 and set a “buy” rating for the company in a report on Friday, November 11th. Wells Fargo & Company dropped their price objective on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a report on Monday, November 14th. UBS Group dropped their price objective on shares of Zentalis Pharmaceuticals to $52.00 in a report on Monday, November 21st. Morgan Stanley decreased their price target on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Friday, November 11th. Finally, HC Wainwright reissued a “buy” rating and set a $55.00 price target on shares of Zentalis Pharmaceuticals in a research note on Thursday. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Zentalis Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $46.56.

Zentalis Pharmaceuticals Trading Up 1.8 %

NASDAQ ZNTL opened at $19.50 on Monday. The firm has a market cap of $1.16 billion, a price-to-earnings ratio of -4.30 and a beta of 1.87. The company has a 50 day moving average of $21.15 and a 200-day moving average of $22.29. Zentalis Pharmaceuticals has a 1-year low of $17.33 and a 1-year high of $52.85.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Matrix Capital Management Company LP raised its holdings in shares of Zentalis Pharmaceuticals by 111.5% during the second quarter. Matrix Capital Management Company LP now owns 9,199,973 shares of the company’s stock worth $258,519,000 after acquiring an additional 4,850,694 shares during the period. FMR LLC raised its holdings in shares of Zentalis Pharmaceuticals by 15.3% during the second quarter. FMR LLC now owns 7,776,168 shares of the company’s stock worth $218,510,000 after acquiring an additional 1,033,474 shares during the period. Avidity Partners Management LP raised its holdings in shares of Zentalis Pharmaceuticals by 21.9% during the fourth quarter. Avidity Partners Management LP now owns 5,150,000 shares of the company’s stock worth $103,721,000 after acquiring an additional 926,900 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Zentalis Pharmaceuticals by 2.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 4,298,551 shares of the company’s stock worth $120,789,000 after acquiring an additional 100,371 shares during the period. Finally, BlackRock Inc. raised its holdings in shares of Zentalis Pharmaceuticals by 2.9% during the third quarter. BlackRock Inc. now owns 3,336,066 shares of the company’s stock worth $72,258,000 after acquiring an additional 95,008 shares during the period.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,624 shares of the firm’s stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $20.42, for a total value of $53,582.08. Following the transaction, the chief financial officer now directly owns 397,275 shares of the company’s stock, valued at $8,112,355.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,624 shares of the firm’s stock in a transaction that occurred on Monday, February 13th. The shares were sold at an average price of $20.42, for a total value of $53,582.08. Following the transaction, the chief financial officer now directly owns 397,275 shares of the company’s stock, valued at $8,112,355.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, President Cam Gallagher sold 3,332 shares of Zentalis Pharmaceuticals stock in a transaction on Monday, February 13th. The stock was sold at an average price of $20.42, for a total transaction of $68,039.44. Following the transaction, the president now directly owns 499,771 shares in the company, valued at $10,205,323.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,763 shares of company stock valued at $873,760. 19.90% of the stock is currently owned by insiders.

About Zentalis Pharmaceuticals

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.